PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Assessment to 2024

PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Assessment to 2024

Code: GDHC121PIDR | Published: Nov-2015 | Pages: 283 | GlobalData
Price :
$10,995.00
USD

* Required Fields

$10,995.00

Details

PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Assessment to 2024

Summary

Dry Eye Syndrome (DES), also known as keratoconjunctivitis sicca, is a multifactorial disease of the tears and ocular surface. This ocular condition can cause ocular discomfort, visual disturbances, and tear film instability, which can potentially damage the ocular surface. The DES market has had few new therapeutics in the last decade with Japan seeing the most change in this time with the arrival of Diquas and Mucosta in 2010 and 2013, respectively. However, the lack of treatment options is about to change with the expected launch of numerous pipeline DES drugs during the forecast period, which will be a significant driver of growth in the 9MM. Indeed, this change has already been initiated with Ikervis recent arrival in Europe in 2015. Furthermore, additional marketing approvals are being sought for currently marketed DES drugs, Restasis and Diquas, in new countries in the 9MM, which will provide a source of growth in this market.

Highlights

Key Questions Answered

- The DES market has been dominated by artificial tears therapy and by Restasis (in the US) for many years, with little approved therapeutic options available in the 9MM. New classes of drugs are anticipated the reach the market within the forecast period. How will these change the market overall during the forecast period? Will Restasis maintain market dominance in 2024?
- The current late stage DES pipeline is varied, with first-in-class drugs in development with innovative modes of action. Which of these will have the biggest impact on the market? What strategies are developers undertaking to penetrate this chronically underserved market? Will these fulfil any unmet needs?
- Population aging is occurring in almost all countries worldwide, particularly in the 9MM. This is expected to have a significant impact on the prevalence of age-related diseases such as DES. How will epidemiological changes impact the growth of the future market?

Key Benefits

- The main driver of growth in the DES market will be the introduction of first-in-class drugs over the forecast period. The launch of these therapies will act as a stimulant for growth in this chronically underserved market.
- DES has been a high risk indication for developers, with numerous drugs failing in late stage development. This has acted as a significant barrier to growth in this market historically.
- The arrival of new therapies across the 9MM will increase treatment rates and provide alternative options for many patients.
- The largest unmet need in the DES market will remain the lack of additional safe and efficacious therapeutics with novel modes of action. In addition, simplifying dosing regimens is an important consideration for companies developing drugs to treat these patients.

Scope

- Overview of DES, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized DES market revenue, annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024.
- Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the glaucoma therapeutics market.
- Pipeline analysis: focus on the four late-stage pipeline DES drugs discussing emerging trends as well as overview of earlier phase drugs.
- Analysis of the current and future market competition in the global DES therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global glaucoma therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global DES therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global DES therapeutics market from 2014-2024.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Alcon
Allergan
Herantis
Mimetogen
Mitotech
Otsuka
RegeneRx
Santen
Shire

Report Format

Following are different modes of Licenses.

a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.

b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.

c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.

Quick Help

1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :

a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]

b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]


2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:

a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
d. Paypal


3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.

If you have a more question about our publications please see our FAQs section or contact us now at cs@marketinforesearch.com.

CUSTOMERS WHO VIEWED THIS REPORT ALSO VIEWED

There are no reports matching the selection.

Browse similar reports by category:
Pharmaceuticals & Healthcare
GlobalData